As mentioned above, while it has been previously shown that H1047R has a superior oncogenic potential than E545K in transgenic mammary cancer models [17], the potential of different PIK3CA mutations in conferring resistance to upstream inhibition has not been previously explored. This evidence concerns the gene PIK3CA and breast cancer.